Funding for this research was provided by:
Japan Society for the Promotion of Science (20K07743, 17K08522, 18K15466)
Ministry of Education, Culture, Sports, Science and Technology (S1411007)
Japan Agency for Medical Research and Development (JP20bm0804003, JP19ek0109244, JP17bm0804003)
Received: 4 September 2020
Accepted: 15 March 2021
First Online: 23 March 2021
Ethics approval and consent to participate
: The genetic analysis in the current study was performed under the guidelines of the recombinant DNA experiments committee of Juntendo University (Approval Number 27-3). The use of human iPSCs was approved by the Ethical Committees of Juntendo University School of Medicine (Approval Number 2017032).
: Not applicable.
: Hideyuki Okano is a founding scientist and a paid scientific advisor of SanbBio Co. Ltd. and K Pharma. Co. Ltd. The other authors declare neither financial nor non-financial competing interests.